What's holding us back is the acceptance of the EDEN unit.
As most here know I'm also invested in AVXL which is going for approval in Europe for their Alzheimer's drug. Like NWBO, they applied in December, but of 2024. There current market cap is just below a billion, but three Analysts following them have their target as $40+, roughly four times what they are today. I believe they could achieve that just prior to approval, late this year, but perhaps not until it occurs.
My point is, this ought to be where we should be, but AVXL has commercial production capability that can handle worldwide distribution with approvals, that's what we lack. It's very possible that the approval of the EDEN unit could be a bigger event than even the UK approval, though clearly we need both.
A market cap in the $4 to $7 billion range represent a $3 to $5 share price in our case, at least ten times + our current price. I can't say it will be this, or next month, but I'd be very surprised if it fails to happen this year.
Gary
Bullish
Market Data 
Markets 
AI
